Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2014-004951-30 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Severely brain injured patients are at high risk of intracranial hypertension. Among medical treatments (sedatives), neuromuscular blocking agents (NMBA) are recommended by french but not english speaking societies.
Effects of NMBA are unknown. The present study is designed to compare the effects of NMBA versus placebo in the treatment of intracranial hypertension, and the underlying physiopathologic effects.
In case of intracranial hypertension, french neurocritical care society argue for the use of neuromuscular blocking agents before osmotherapy, barbituric coma, hypothermia and craniectomy.
English speaking societies don't sustain this approach. Since then, the use of NMBA remains controversial in case of intracranial hypertension and no study is available.
We propose to study severely brain injured patients presenting with intracranial hypertension and treat them with cisatracurium besilate or placebo.
Our hypothesis is that neuromuscular blockade might act on several parameters:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CISATRACURIUM | Experimental | To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo. |
|
| PLACEBO | Placebo Comparator | To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| cisatracurium besilate | Drug |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| area under the curve of the temporal evolution of intracranial pressure | The primary outcome is the area under the curve of the temporal evolution of intracranial pressure, over a period of 30 minutes after the administration of neuromuscular blocking agent or placebo. | at day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Course of intracranial and cerebral perfusion pressures and various cerebral monitoring data if available (SvjO2, PtiO2) | at day 1 | |
| Monitoring of the time spent by intracranial pressure above 20 mmHg using continuous recording | at day 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Patrick LACARIN | Contact | 04 73 75 11 95 | placarin@chu-clermontferrand.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Clermont-Ferrand | Recruiting | Clermont-Ferrand | 63003 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Course of intracranial pressure based on the type of brain injury | diffuse axonal injury, subarachnoid hemorrhage, intracerebral hematoma) | at day 1 |
| Monitoring of the curare effect | train of four and PTC | at day 1 |
| Course of ventilation parameters | tidal volume, FiO2, PEEP | at day 1 |
| Course of transcranial Doppler data | velocities | at day 1 |
| Course of arterial blood gas data | pH, paO2, paCO2, Excess Base, HCO3- | at day 1 |
| Course of plasma and cerebrospinal fluid concentrations of cistracurium and laudanosine | at day 1 |
| Cerebrospinal fluid concentrations of cisatracurium and laudanosin in case of cerebrospinal fluid derivation | at day 1 |
| Occurrence of cardiovascular complications | hypotension, myocardial ischemia | at day 1 |
| Occurrence of pulmonary complications | acute respiratory distress syndrome, pneumonia acquired under mechanical ventilation | at day 1 |
| Occurrence of renal complications | use of renal replacement therapy | at day 1 |
| Occurrence of infectious complications | at day 1 |
| Doses of vasopressors or catecholamines | at day 1 |
| Need to increase therapeutics | barbiturate coma, hypothermia, osmotherapy, decompressive craniectomy | at day 1 |
| ID | Term |
|---|---|
| D000070642 | Brain Injuries, Traumatic |
| D019586 | Intracranial Hypertension |
| ID | Term |
|---|---|
| D001930 | Brain Injuries |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D006259 | Craniocerebral Trauma |
| D020196 | Trauma, Nervous System |
| D014947 | Wounds and Injuries |
Not provided
Not provided
| ID | Term |
|---|---|
| C101584 | cisatracurium |
Not provided
Not provided
Not provided